This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript

Cadence Pharmaceuticals Inc. ( CADX)

Q3 2010 Earnings Call

November 5, 2010 8:30 AM ET

Executives

Ted Schroeder – President and CEO

Jim Breitmeyer – Executive Vice President and CMF

Scott Byrd – Senior Vice President and CCO

Bill LaRue – Senior Vice President and CFO.

Analysts

Charles Duncan – JMP Securities

Eric Schmidt – Cowen and Company

Adam Cutler – Canaccord Genuity

Joseph Schwartz – Leerink Swann

Irina Rivkind – Duncan Williams

Richard Lau – Wedbush Securities

Presentation

Operator

Good morning. And welcome to the Cadence Pharmaceuticals Third Quarter 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Jim Breitmeyer, Executive Vice President and Chief Medical Officer; Scott Byrd, Senior Vice President and Chief Commercial Officer; and Bill LaRue, Senior Vice President and Chief Financial Officer.

At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company we will open the conference for question-and-answer after the management presentation. (Operator Instructions)

Our first speaker is Bill LaRue. Please go ahead, sir.

Bill LaRue

Thank you. Good morning, everyone. Before we get started today, I’d like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding our readiness for and anticipated timing for the planned commercial launch of OFIRMEV, OFIRMEV’s market potential and ability to fulfill unmet medical needs, our beliefs that pharmacoeconomic issues will not be a significant barrier to formulary approvals, the sufficiency of our company’s capital resources to fund our operations through the launch of OFIRMEV and our financial estimates or projections.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs